Back

Inherited genetic risk factors in young-onset lung cancer

Esai Selvan, M.; Gould Rothberg, B. E.; Patel, A. A.; Sang, J.; Horowitz, A.; Christiani, D. C.; Klein, R. J.; Gumus, Z. H.

2026-04-15 genetic and genomic medicine
10.64898/2026.04.14.26350822 medRxiv
Show abstract

IntroductionLung cancer is rare before age 45, and its inherited genetic basis remains poorly defined. MethodsWe performed whole-genome sequencing in 171 predominantly young-onset lung cancer patients and integrated these data with whole-exome sequencing from six major lung cancer consortia, yielding 9,065 patients. After quality control, analyses focused on 6,545 individuals of European ancestry, the largest ancestral group. We compared the prevalence of rare pathogenic and likely pathogenic (P/LP) germline variants between 186 young-onset (age <45 years) and 6,359 older patients at gene and gene-set levels using Fishers exact test, stratified by histology, sex, and smoking status. Polygenic risk scores (PRS) derived from common variants were also evaluated. ResultsYoung-onset patients carried a higher burden of rare germline P/LP variants in DNA damage response (DDR) genes (including BRIP1, ERCC6, MSH5), and in cilia-related genes, notably GPR161. At the pathway level, DDR genes were significantly enriched (OR=1.66, p=0.007), with the strongest signal in the Fanconi Anemia pathway and among females (OR=1.96, p=0.01). Enrichment was also observed in inborn errors of immunity pathways, with strongest signals in antibody deficiency and the complement system genes. Young-onset patients additionally exhibited higher lung cancer PRS. ConclusionYoung-onset lung cancer exhibits a distinct germline genetic architecture, characterized by enrichment of rare P/LP variants in DDR, cilia-related, and immune pathways, and an elevated lung cancer PRS. These findings support a greater role for inherited susceptibility in early-onset disease and have implications for risk stratification, earlier screening, and precision prevention.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Genetics in Medicine
69 papers in training set
Top 0.1%
14.9%
2
Genome Medicine
154 papers in training set
Top 0.4%
10.3%
3
Nature Communications
4913 papers in training set
Top 17%
10.3%
4
European Journal of Human Genetics
49 papers in training set
Top 0.1%
6.5%
5
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.1%
4.9%
6
Cancers
200 papers in training set
Top 2%
3.6%
50% of probability mass above
7
Clinical Epigenetics
53 papers in training set
Top 0.3%
3.6%
8
Annals of Oncology
13 papers in training set
Top 0.3%
2.8%
9
Journal of Medical Genetics
28 papers in training set
Top 0.2%
2.1%
10
Human Molecular Genetics
130 papers in training set
Top 1%
1.9%
11
Scientific Reports
3102 papers in training set
Top 54%
1.8%
12
JNCI Cancer Spectrum
10 papers in training set
Top 0.2%
1.7%
13
European Respiratory Journal
54 papers in training set
Top 1%
1.2%
14
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
15
Nature Genetics
240 papers in training set
Top 6%
1.2%
16
eBioMedicine
130 papers in training set
Top 3%
1.0%
17
The American Journal of Human Genetics
206 papers in training set
Top 3%
1.0%
18
The Journal of Molecular Diagnostics
36 papers in training set
Top 0.3%
1.0%
19
npj Genomic Medicine
33 papers in training set
Top 0.7%
0.9%
20
PLOS ONE
4510 papers in training set
Top 63%
0.9%
21
ERJ Open Research
44 papers in training set
Top 0.7%
0.9%
22
BMC Medical Genomics
36 papers in training set
Top 0.9%
0.9%
23
Journal of Internal Medicine
12 papers in training set
Top 0.5%
0.8%
24
Frontiers in Oncology
95 papers in training set
Top 3%
0.8%
25
Cancer Discovery
61 papers in training set
Top 2%
0.8%
26
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.6%
0.8%
27
JAMA Network Open
127 papers in training set
Top 4%
0.8%
28
npj Precision Oncology
48 papers in training set
Top 1%
0.8%
29
Human Mutation
29 papers in training set
Top 0.7%
0.8%
30
eLife
5422 papers in training set
Top 59%
0.7%